LEADER 02173nam  22006373  450 
001 9910297034703321
005 20241204165700.0
010   $a9783845232188
010   $a3845232188
035   $a(CKB)4340000000010258
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/55773
035   $a(MiAaPQ)EBC7430476
035   $a(Au-PeEL)EBL7430476
035   $a(ScCtBLL)944d0c35-c4d6-4445-b164-71dc8a5937b9
035   $a(OCoLC)1079760018
035   $a(oapen)doab55773
035   $a(OCoLC)44207881
035   $a(EXLCZ)994340000000010258
100   $a20240418d2024      uy         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200   $aPatentability of Chemical Selection Inventions
205   $aFirst edition.
210   $cNomos Verlagsgesellschaft mbH & Co. KG$d2011
210  1$aLa Vergne :$ce-book,$d2024.
210  4$dİ2024.
215   $a1 online resource (75 pages) $cillustrations
225 0 $aMunich Intellectual Property Law Center - MIPLC.
300   $aOriginally presented as the author's thesis--Universita?t Mu?nchen, 2010.
311 08$a9783832965242 
311 08$a3832965246 
320   $aIncludes bibliographical references (pages 69-75).
330   $aThe thesis is a response to the recent decisions of the German Federal Court of Justice on the patentability requirements of selection inventions, namely, the Olanzapine and Escitalopram decisions.
606   $aDrugs$vPatents
606   $aPatent laws and legislation$vCases
606   $aConflict of laws$xPatents$vCases
606   $aDrug development
606   $aOlanzapine
606   $aCitalopram
615  0$aDrugs
615  0$aPatent laws and legislation
615  0$aConflict of laws$xPatents
615  0$aDrug development.
615  0$aOlanzapine.
615  2$aCitalopram.
700   $aAhn$b Hyewon$0899875
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910297034703321
996   $aPatentability of Chemical Selection Inventions$94155955
997   $aUNINA